Australian Clinical Guidelines for Acute Myeloid Leukaemia
Version 1.0 | Published February 2025
The Australian Clinical Guidelines for Acute Myeloid Leukaemia (AML) help healthcare professionals deliver standardised, evidence-based treatment for people diagnosed with one of the most aggressive blood cancers.
The Blood Cancer Taskforce, supported by the Leukaemia Foundation, collaborated with leading Australian haematologists and infectious diseases experts and key organisations to develop the AML treatment guidelines. These provide a framework for care and treatment pathways that are designed for our clinical settings. They also align with National Health and Medical Research Council standards and focus on pharmaceutical therapies for adults with the goal of improving the efficacy of treatments and survival rates, while considering regulatory requirements.
The guidelines provide specific recommendations for healthcare professionals including:
- Pharmaceutical treatments including induction, consolidation and maintenance therapy
- Antimicrobial prophylaxis to manage infections in AML patients
- Emerging and novel treatments
- Clinical trial opportunities
- Access and Pharmaceutical Benefits Scheme funding implications
Access the guidelines
The guidelines should only be used by healthcare professionals to guide clinical decision making.
Patients and families should refer to the Optimal Care Pathway for AML if they are seeking additional medical information about treatment for AML. This document outlines what high-quality care should look like at every stage of the patient journey. Patients should always consult with their healthcare provider for any concerns or questions about treatment.
The Australian Clinical Guidelines for Acute Myeloid Leukaemia were developed by the Blood Cancer Taskforce supported by Leukaemia Foundation, Haematology Society of Australia and New Zealand, Australasian Leukaemia and Lymphoma Group, and haematology and infectious disease experts. This work was funded by the Department of Health and Aged Care.